drugset / Trial / NCT01167127

Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant Pain

NCT01167127

Phase 3 Completed 113 enrolled Mundipharma Pharmaceuticals B.V.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of the study is to observe the OXN treatment of patients with moderate to severe non-malignant pain in daily clinical practise with respect to pain relief and bowel function. Patients who have insufficient pain relief and/or unacceptable side effects with the previous analgesic treatment WHO step 1 or 2 and require around-the-clock opioid therapy can be included in the study.

Timeline

Start
2009-06
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naloxone Small molecule Oral
Comparator Oxycodone Other / unclassified Oral

Indications

No indication recorded.